Literature DB >> 3855392

Function following mega total hip arthroplasty compared with conventional total hip arthroplasty and healthy matched controls.

R Johnsson, A Carlsson, K Kisch, U Moritz, R Zetterström, B M Persson.   

Abstract

Total hip arthroplasty (THA) with the use of a Mega prosthesis was a successful surgical procedure in the management of tumors of the hip as well as in revision THA with loss of bone stock. Passive hip motion and strength of hip muscles, walking ability, and activities of daily living in nine such cases compared well with the function following conventional THA. Limp and positive Trendelenburg sign were more common after Mega THA. Dislocation of the prosthesis occurred in 2/14 cases. Fracture of the femoral condyle occurred in one case. Another case had stem fatigue failure of a thin stem.

Entities:  

Mesh:

Year:  1985        PMID: 3855392

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  4 in total

1.  Quality of life following proximal femoral replacement using a modular system in revision THA.

Authors:  Muhyeddine M Al-Taki; Bassam A Masri; Clive P Duncan; Donald S Garbuz
Journal:  Clin Orthop Relat Res       Date:  2011-02       Impact factor: 4.176

2.  Early results of the LPS™ limb preservation system in the management of periprosthetic femoral fractures.

Authors:  M Curtin; C Bryan; E Murphy; C G Murphy; W Curtin
Journal:  J Orthop       Date:  2016-10-25

3.  Hip abductor moment arm--a mathematical analysis for proximal femoral replacement.

Authors:  Eric R Henderson; German A Marulanda; David Cheong; H Thomas Temple; G Douglas Letson
Journal:  J Orthop Surg Res       Date:  2011-01-25       Impact factor: 2.359

4.  Proximal femoral reconstruction with modular megaprostheses in non-oncological patients.

Authors:  Kevin Döring; Klemens Vertesich; Luca Martelanz; Kevin Staats; Christoph Böhler; Christian Hipfl; Reinhard Windhager; Stephan Puchner
Journal:  Int Orthop       Date:  2021-07-14       Impact factor: 3.075

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.